Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03852264 · ClinicalTrials.gov registry record · NA
Oxytocin Pathways and the Health Effects of Human-Animal Interaction
A NA study, sponsored by University of Arizona.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT03852264: Completed NA study, sponsored by University of Arizona.
NCT03852264 is a NA study that has completed, run by University of Arizona. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03852264, a NA study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study investigates the roles of oxytocin pathways in human-animal interaction.
Primary Outcome
Change from baseline measured as the area under the curve with respect to the initial value (AUCi).
Interventions
- BEHAVIORAL Pet dog
- BEHAVIORAL Unfamiliar dog
- BEHAVIORAL Nonsocial control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2019-03-08 |
| Est. Completion | 2022-01-10 |
| Phase | NA |
What the finished NCT03852264 record still lists
NCT03852264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Pet dog is the first listed.
NCT03852264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03852264 about?
NCT03852264 is a clinical study titled "Oxytocin Pathways and the Health Effects of Human-Animal Interaction". This study investigates the roles of oxytocin pathways in human-animal interaction.
What is the current status of trial NCT03852264?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2019-03-08. Estimated completion is 2022-01-10.
What interventions are being tested in trial NCT03852264?
The interventions under investigation include: Pet dog (BEHAVIORAL), Unfamiliar dog (BEHAVIORAL), Nonsocial control (BEHAVIORAL).
Who is sponsoring clinical trial NCT03852264?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03852264's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI